Revance Therapeutics (RVNC) to Release Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Revance Therapeutics to post earnings of ($0.66) per share for the quarter.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.17. The company had revenue of $69.80 million for the quarter, compared to analyst estimates of $64.02 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $3.77 on Friday. Revance Therapeutics has a 1-year low of $3.21 and a 1-year high of $37.98. The firm has a fifty day moving average of $4.85 and a two-hundred day moving average of $6.34. The firm has a market cap of $392.91 million, a P/E ratio of -0.99 and a beta of 1.16.

Insider Activity at Revance Therapeutics

In related news, insider Dwight Moxie sold 8,125 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $40,950.00. Following the completion of the transaction, the insider now directly owns 137,815 shares in the company, valued at approximately $694,587.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Dwight Moxie sold 8,125 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $40,950.00. Following the completion of the transaction, the insider now owns 137,815 shares in the company, valued at approximately $694,587.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Tobin Schilke sold 9,361 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total transaction of $47,179.44. Following the completion of the transaction, the chief financial officer now owns 192,666 shares of the company’s stock, valued at approximately $971,036.64. The disclosure for this sale can be found here. Insiders sold a total of 29,089 shares of company stock worth $143,642 in the last ninety days. 5.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on RVNC shares. Barclays decreased their price target on shares of Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, January 29th. Piper Sandler reduced their target price on shares of Revance Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, February 29th. The Goldman Sachs Group boosted their target price on shares of Revance Therapeutics from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, March 1st. Mizuho downgraded shares of Revance Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $9.00 in a research report on Monday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Revance Therapeutics in a research report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $13.75.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.